Acquisitions - Reata Pharmaceuticals, Inc. (Details) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	Sep. 26, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Business Combination [Line Items]
Selling, general and administrative		$ 2,433.6	$ 2,403.7	$ 2,549.7
Long-term debt, gross		6,567.3
Reata Pharmaceuticals, Inc
Business Combination [Line Items]
Price per share (in dollars per share)	$ 172.50
Total transaction value	$ 6,602.9
Outstanding equity awards		$ 983.9
Consideration transferred, equity compensation pre-acquisition services	590.5
Operating expenses	393.4
Selling, general and administrative	196.4
Research and development expense	197.0
Reata Pharmaceuticals, Inc | Secured Debt | The Credit Facility | Line of Credit
Business Combination [Line Items]
Long-term debt, gross	$ 1,000.0